Boudou C, Mattio L, Koval A, Soulard V, Katanaev VL. Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1045102][Reference Citation Analysis]
2
Phillips C, Bhamra I, Eagle C, Flanagan E, Armer R, Jones CD, Bingham M, Calcraft P, Edmenson Cook A, Thompson B, Woodcock SA. The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models. Cancer Research Communications 2022;2:914-928. [DOI: 10.1158/2767-9764.crc-21-0095][Reference Citation Analysis]